Japan

Two patented drugs for the treatment of diabetes - Novo Nordisk's Victoza (liraglutide) and Novartis's Equa (vildagliptin) - have been registered in Japan. Despite the current popularity... 2010-01-21

Japan is the most attractive market for multinational drugmakers operating in Asia Pacific, according to BMI's recently compiled Q210 Pharmaceuticals & Healthcare Business Environment... 2010-01-11

BMI's Drug Expenditure Forecast Model reveals that medicine sales in Asia Pacific will more than double over the next decade. Key drivers of growth are expanding economies, rising... 2009-12-21

BMI is maintaining its short- and long-term forecasts for Japan's pharmaceutical market, despite the announcement of a possible 6.2% price cut to prescription drugs next year. This... 2009-12-04

One of BMI's core views for the pharmaceuticals and healthcare industry is that emerging markets will drive global medicine sales. However, not all drugmakers subscribe to this opinion.... 2009-09-17

The US leads BMI's global Pharmaceuticals & Healthcare Business Environment Ratings with a score of 72.4 out of 100. It is the world's largest market for medicines, with a well-established... 2009-09-09

Pharmaceutical sales in Japan are forecast to grow by a modest 1.95% in local currency terms during 2009. This rate of expansion is below the 2004-08 compound annual growth rate (CAGR)... 2009-08-13